Medication Related Osteonecrosis of Jaws and Current Treatment Modalities

Yıl 2019, Cilt: 28 Sayı: 4, 285 - 299, 31.12.2019

Aras Erdil , Emrah Soylu , Ahmet Altan , Nihat Akbulut

https://doi.org/10.17827/aktd.458351

Öz

Recently defined, medication related osteonecrosis of the jaws (MRONJ), resulting from maxillofacial surgical procedures applied during or after bisphosphonate, antiresorptive and antiangiogenic treatments is a newly defined disease and still its etiopathogenesis is unexplained. There are still debates on the treatment approaches of the disease, and the commission established by the American Association for Maxillofacial Surgery publishes guidelines on the definition, staging and treatment approaches of the disease. Nowadays, current, accepted methods of treatment of the disease are conservative methods. It is of utmost importance that patients, who refer to oral and maxillofacial surgeons, are informed about this disease and are motivated about preventive methods. In this review, the most recent articles published in the literature about the applied treatments until 2018 were compiled after the guidance in 2014.

Anahtar Kelimeler

Bisphosphonate-Associated Osteonecrosis of the Jaw, Osteonecrosis, Alendronate, Angiogenesis Inhibitors

Çenelerin İlaca Bağlı Osteonekrozu ve Güncel Tedavi Yaklaşımları

Öz

Son dönemde bisfosfanat, antirezorptif ve antianjiyogenik tedaviler esnasında veya sonrasında uygulanan maksillofasyal cerrahi işlemler ile ortaya çıkan çenelerin ilaca bağlı osteonekrozu (MRONJ) yeni tanımlanan ve halen daha etyopatogenezi tam anlaşılamamış bir hastalıktır. Hastalığın tedavi yaklaşımları konusunda da henüz tartışmalar devam etmekte olup Amerikan Maksillofasyal Cerrahlar Birliği tarafından oluşturulan komisyon tarafından hastalığın tanımı, evrelendirilmesi ve tedavi yaklaşımları konusunda çalışmalar değerlendirilmekte ve görüş bildiren kılavuzlar yayınlanmaktadır. Hastalığın tedavisi hakkında günümüzde, güncel, kabul edilen yöntemler konservatif yöntemlerdir. Ağız, diş ve çene cerrahlarına başvuran hastaların bu hastalık hakkında bilgilendirilmesi ve koruyucu yöntemler hakkında motive edilmeleri büyük önem taşımaktadır. Bu derlemede en son yayınlanan 2014 yılındaki kılavuz sonrası 2018 yılına kadar literatürde bildirilen uygulanmış tedavileri konu alan makaleler derlenmiştir

Anahtar Kelimeler

Çenenin Bifosfonat İlişkili Osteonekrozu, Osteonekroz, Alendronat, Anjiyogenez İnhibitörleri

Kaynakça

• 1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-1117. http://www.ncbi.nlm.nih.gov/pubmed/12966493. Accessed April 3, 2017.
• 2. Ruggiero SL, Dodson TB. American Association of Oral and Maxillofacial Surgeons position Paper on Medication-Related Osteonecrosis of the Jaws- 2014 Update. Am Assoc Oral Maxillofac Surg. 2014;72(12):2381-2382. doi:10.1016/j.joms.2014.08.017.
• 3. Fleisch HA, Russell RGG, Bisaz S, Hlbauer RCM. The Inhibitory Effect of Phosphonates on the Formation of Calcium Phosphate Crystals in vitro and on Aortic and Kidney Calcification in vivo. 1970;18:12-18.
• 4. Sinclair HM. the Editor. Lancet. 1958;vi:1957-1959.
• 5. Bartel R, Frisch B, Tresckow E Von, Bartl C. Bisphosphonates in Medical Practice.; 2007. doi:10.1007/978-3-540-69870-8.
• 6. Vile R. Cancer therapy: Less blood means more sanguinity. Curr Biol. 1995;5(1):10-13. doi:10.1016/S0960-9822(95)00004-2.
• 7. Brunello A, Saia G, Bedogni A, Scaglione D, Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone. 2009;44(1):173-175. doi:10.1016/j.bone.2008.08.132.
• 8. Pageau SC. Denosumab. MAbs. 2009;1(3):210-215. doi:10.4161/mabs.1.3.8592.
• 9. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-831. doi:10.1056/NEJMoa044459.
• 10. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2010;48(3):221-223. doi:10.1016/j.bjoms.2009.08.030.
• 11. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic [1]. J Oral Maxillofac Surg. 2003;61(9):1115-1117.
• 12. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61(9):1104-1107. http://www.ncbi.nlm.nih.gov/pubmed/12966490. Accessed April 3, 2017.
• 13. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21(22):4253-4254. doi:10.1200/JCO.2003.99.132.
• 14. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527-534. http://www.ncbi.nlm.nih.gov/pubmed/15122554. Accessed April 3, 2017.
• 15. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the Jaw in a Patient on Denosumab. J Oral Maxillofac Surg. 2010;68(5):959-963. doi:10.1016/j.joms.2009.10.010.
• 16. Stopeck AT, Lipton A, Body J-J, et al. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. J Clin Oncol. 2010;28(35):5132-5139. doi:10.1200/JCO.2010.29.7101.
• 17. Henry DH, Costa L, Goldwasser F, et al. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. J Clin Oncol. 2011;29(9):1125-1132. doi:10.1200/JCO.2010.31.3304.
• 18. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341-1347. doi:10.1093/annonc/mdr435.
• 19. Wyngaert T Van Den, Wouters K, Huizing MT, Vermorken JB. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw ( ONJ ): non bis in idem ? 2011:2035-2040. doi:10.1007/s00520-010-1061-0.
• 20. Paper AP. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of. 2007:369-376. doi:10.1016/j.joms.2006.11.003.
• 21. Otto S. Medication-Related Osteonecrosis of the Jaw. Vol 27. (Otto S, ed.). Springer Berlin Heidelberg; 2015. doi:10.1016/j.coms.2015.06.002.
• 22. Mehanna P, Goddard R. Bisphosphonate associated osteonecrosis: an unusual case. Aust Dent J. 2010;55(3):311-313. doi:10.1111/j.1834-7819.2010.01240.x.
• 23. Soda T, Fukumoto R, Hayashi T, Oka D, Fujimoto N, Koide T. [Case of prostate cancer associated with bisphosphonate-related osteonecrosis of the jaw followed by retropharyngeal abscess]. Hinyokika Kiyo. 2013;59(9):587-591. http://www.ncbi.nlm.nih.gov/pubmed/24113758. Accessed April 3, 2017.
• 24. Yamada C, Takahata S, Nakagawa K, Yamamoto N, Kogo M. Brain abscess secondary to medication-induced osteonecrosis of the jaw. J Oral Maxillofac Surgery, Med Pathol. 2016;28(5):438-441. doi:10.1016/j.ajoms.2016.04.007.
• 25. Otto S, Hafner S, Grötz KA. The Role of Inferior Alveolar Nerve Involvement in Bisphosphonate-Related Osteonecrosis of the Jaw. J Oral Maxillofac Surg. 2009;67(3):589-592. doi:10.1016/j.joms.2008.09.028.
• 26. Assaf AT, Jürgens TP, Benecke AW, et al. Numb chin syndrome: a rare and often overlooked symptom. J oral facial pain headache. 2014;28(1):80-90. http://www.ncbi.nlm.nih.gov/pubmed/24482791. Accessed April 3, 2017.
• 27. Patel S, Choyee S, Uyanne J, et al. Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. doi:10.1111/j.1601-0825.2012.01911.x.
• 28. Longo F, Guida A, Aversa C, et al. Platelet Rich Plasma in the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw : Personal Experience and Review of the Literature. 2014;2014. doi:10.1155/2014/298945.
• 29. Magremanne M, Reychler H. Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. J Oral Maxillofac Surg. 2014;72(2):334-337. doi:10.1016/j.joms.2013.06.188.
• 30. Ikeda T, Kuraguchi J, Kogashiwa Y, Yokoi H, Satomi T, Kohno N. Successful treatment of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) patients with sitafloxacin: New strategies for the treatment of BRONJ. Bone. 2015;73:217-222. doi:10.1016/j.bone.2014.12.021.
• 31. Bodem JP, Kargus S, Engel M, Hoffmann J, Freudlsperger C. Value of nonsurgical therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw. J Cranio-Maxillofacial Surg. 2015;43(7):1139-1143. doi:10.1016/j.jcms.2015.05.019.
• 32. Zandi M, Dehghan A, Ghadermazi K, Malekzadeh H, Akbarzadeh M. Perioperative discontinuation of intravenous bisphosphonate therapy reduces the incidence and severity of bisphosphonate-related osteonecrosis of the jaw: A randomized, controlled, prospective experimental study in rats. J Craniomaxillofac Surg. 2015;43(9):1823-1828. doi:10.1016/j.jcms.2015.08.008.
• 33. Çapar GD, Sapmaz-Metin M, Kütan E, et al. Preventive effect of doxycycline sponge against bisphosphonate-related osteonecrosis of the jaws: an animal study. Biotechnol Biotechnol Equip. 2016;30(4):752-761. doi:10.1080/13102818.2016.1174078.
• 34. Karasneh JA, Al-Eryani K, Clark GT, Sedghizadeh PP. Modified protocol including topical minocycline in orabase to manage medication-related osteonecrosis of the jaw cases. J Oral Pathol Med. 2016;45(9):718-720. doi:10.1111/jop.12419.
• 35. Matsumoto A, Sasaki M, Schmelzeisen R, Oyama Y, Mori Y, Voss PJ. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. Clin Oral Investig. 2016:1-8. doi:10.1007/s00784-016-1762-y.
• 36. Laimer J, Steinmassl O, Hechenberger M, Rasse M, Pikula R, Bruckmoser E. Intraoral Vacuum-Assisted Closure Therapy—A Pilot Study in Medication-Related Osteonecrosis of the Jaw. J Oral Maxillofac Surg. 2017. doi:10.1016/j.joms.2017.02.033.
• 37. Kim JW, Kim SJ, Kim MR. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: A prospective feasibility study. Br J Oral Maxillofac Surg. 2014;52(9):854-859. doi:10.1016/j.bjoms.2014.07.256.
• 38. Sarkarat F, Motamedi MHK, Jahanbani J, Sepehri D, Kahali R, Nematollahi Z. Platelet-rich plasma in treatment of zoledronic acid-induced bisphosphonate-related osteonecrosis of the jaws. Trauma Mon. 2014;19(2):13-17. doi:10.5812/traumamon.17196.
• 39. Anitua E, Zalduendo M, Troya M, Orive G. PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells. Clin Oral Investig. 2016;20(3):513-521. doi:10.1007/s00784-015-1528-y.
• 40. Lopez-Jornet P, Sanchez Perez A, Amaral Mendes R, Tobias A. Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A??systematic review. J Cranio-Maxillofacial Surg. 2016;44(8):1067-1072. doi:10.1016/j.jcms.2016.05.004.
• 41. Tsai L-L, Huang Y-F, Chang Y-C. Treatment of bisphosphonate-related osteonecrosis of the jaw with platelet-rich fibrin. J Formos Med Assoc. 2016;115(7):585-586. doi:10.1016/j.jfma.2015.10.005.
• 42. Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y. Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clin Oral Investig. 2016:1-8. doi:10.1007/s00784-016-2004-z.
• 43. Park J-H, Kim J-W, Kim S-J. Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw? J Oral Maxillofac Surg. 2017. doi:http://dx.doi.org/10.1016/j.joms.2016.12.005.
• 44. Harper RP, Fung E, Reginster JY, al. et. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg. 2007;65(3):573-580. doi:10.1016/j.joms.2006.10.076.
• 45. Yamazaki T, Takahashi K, Bessho K. Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment. Rev Recent Clin Trials. 2014;9(1):37-52. doi:10.2174/1574887109666140423120614.
• 46. Kim KM, Park W, Oh SY, et al. Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw. Osteoporos Int. 2014;25(5):1625-1632. doi:10.1007/s00198-014-2622-8.
• 47. Kakehashi H, Ando T, Minamizato T, et al. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: Preliminary findings. Int J Oral Maxillofac Surg. 2015;44(12):1558-1564. doi:10.1016/j.ijom.2015.07.018.
• 48. Pelaz A, Junquera L, Gallego L, García-Consuegra L, Junquera S, Gómez C. Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide. Med Oral Patol Oral Cir Bucal. 2014;19(4). doi:10.4317/medoral.19458.
• 49. Zandi M, Dehghan A, Mohammadi-Mofrad A, Amini P, Vahdatinia F. Short-Term Perioperative Teriparatide Therapy for the Prevention of Medication-Related Osteonecrosis of the Jaw: A Randomized, Controlled Preclinical Study in Rats. Vol 45. Elsevier Ltd; 2017. doi:10.1016/j.jcms.2016.12.010.
• 50. Ferlin A, Pepe A, Facciolli A, Gianesello L, Foresta C. Relaxin stimulates osteoclast differentiation and activation. Bone. 2010;46(2):504-513. doi:10.1016/j.bone.2009.10.007.
• 51. Bayram B, Uckan S, Develi T, et al. Does relaxin treat BRONJ or prevent the development of BRONJ?: An experimental study in rats. J Oral Maxillofac Surg. 2014;72(9):e41-e42. doi:10.1016/j.joms.2014.06.069.
• 52. Munoz F, Lopez-Pena M, Mino N, Gomez-Moreno G, Guardia J, Cutando A. Topical application of melatonin and growth hormone accelerates bone healing around dental implants in dogs. Clin Implant Dent Relat Res. 2012;14(2):226-235. doi:10.1111/j.1708-8208.2009.00242.x.
• 53. Rodríguez-Lozano FJ, García-Bernal D, De Los Ángeles Ros-Roca M, et al. Cytoprotective effects of melatonin on zoledronic acid-treated human mesenchymal stem cells in vitro. J Cranio-Maxillofacial Surg. 2015;43(6):855-862. doi:10.1016/j.jcms.2015.04.012.
• 54. Basso FG, Turrioni APS, Soares DG, Bagnato VS, Hebling J, de Souza Costa CA. Low-level laser therapy for osteonecrotic lesions: effects on osteoblasts treated with zoledronic acid. Support Care Cancer. 2014;22(10):2741-2748. doi:10.1007/s00520-014-2267-3.
• 55. Porcaro G, Amosso E, Scarpella R, Carini F. Doxycycline fluorescence-guided Er:YAG laser ablation combined with Nd:YAG/diode laser biostimulation for treating bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119(1):e6-e12. doi:10.1016/j.oooo.2014.04.014.
• 56. Vescovi P, Meleti M, Merigo E, et al. Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd: YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal. 2013;18(4):1-6. doi:10.4317/medoral.18812.
• 57. Heggendorn FL, Leite TC, Cunha KSG, et al. Bisphosphonate-related osteonecrosis of the jaws: Report of a case using conservative protocol. Spec Care Dentist. 2016;36(1):43-47. doi:10.1111/scd.12143.
• 58. Minamisako MC, Ribeiro GH, Lisboa ML, Mariela M, Cordeiro R, Grando LJ. Case Report Medication-Related Osteonecrosis of Jaws: A Low-Level Laser Therapy and Antimicrobial Photodynamic Therapy Case Approach. 2016;2016. doi:10.1155/2016/6267406.
• 59. Rotaru H, Kim MK, Kim SG, Park YW. Pedicled buccal fat pad flap as a reliable surgical strategy for the treatment of medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2015;73(3):437-442. doi:10.1016/j.joms.2014.09.023.
• 60. Berrone M, Florindi FU, Carbone V, Aldiano C, Pentenero M. Stage 3 medication-related osteonecrosis of the posterior maxilla: Surgical treatment using a pedicled buccal fat pad flap: Case reports. J Oral Maxillofac Surg. 2015;73(11):2082-2086. doi:10.1016/j.joms.2015.06.165.
• 61. Otto S, Ristow O, Pache C, et al. Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study. J Cranio-Maxillofacial Surg. 2016;44(8):1073-1080. doi:10.1016/j.jcms.2016.05.018.
• 62. Melville JC, Tursun R, Shum JW, Young S, Hanna IA, Marx RE. A technique for the treatment of oral???antral fistulas resulting from medication-related osteonecrosis of the maxilla: the combined buccal fat pad flap and radical sinusotomy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(3):287-291. doi:10.1016/j.oooo.2016.03.015.
• 63. Mücke T, Koerdt S, Jung M, et al. The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws. J Cranio-Maxillofacial Surg. 2016;44(4):369-373. doi:10.1016/j.jcms.2015.12.017.
• 64. Mücke T, Jung M, Koerdt S, Mitchell DA, Loeffelbein D, Kesting MR. Free flap reconstruction for patients with bisphosphonate related osteonecrosis of the jaws after mandibulectomy. J Cranio-Maxillofacial Surg. 2016;44(2):142-147. doi:10.1016/j.jcms.2015.11.015.
• 65. Neto T, Horta R, Balhau R, et al. Resection and microvascular reconstruction of bisphosphonate-related osteonecrosis of the jaw: The role of microvascular reconstruction. Head Neck. 2016;38(8):1278-1285. doi:10.1002/hed.24395.
• 66. Kim H, Hwang J, Ahn K. Fibula Free Flap for Mandibular Reconstruction using Simulation Surgery in Bisphosphonate related Osteonecrosis of the Jaw. 2015;2(1):1-6.
• 67. Matsuura Y, Atsuta I, Ayukawa Y, et al. Therapeutic interactions between mesenchymal stem cells for healing medication-related osteonecrosis of the jaw. Stem Cell Res Ther. 2016;7(1):119. doi:10.1186/s13287-016-0367-3.
• 68. Ogata K, Katagiri W, Hibi H. Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro. Clin Oral Investig. 2016:1-10. doi:10.1007/s00784-016-1986-x.
• 69. Voss PJ, Matsumoto A, Alvarado E, Schmelzeisen R, Duttenhöfer F, Poxleitner P. Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells. Odontology. 2017. doi:10.1007/s10266-017-0295-4.